{"id":"NCT02623699","sponsor":"Biogen","briefTitle":"An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)","officialTitle":"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-20","primaryCompletion":"2021-07-16","completion":"2021-07-16","firstPosted":"2015-12-08","resultsPosted":"2023-07-28","lastUpdate":"2023-07-28"},"enrollment":176,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Amyotrophic Lateral Sclerosis"],"interventions":[{"type":"DRUG","name":"Tofersen","otherNames":["BIIB067","QALSODY"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Part A-SAD: Combined Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part A-SAD: Cohort 1: Tofersen 10 mg","type":"EXPERIMENTAL"},{"label":"Part A-SAD: Cohort 2: Tofersen 20 mg","type":"EXPERIMENTAL"},{"label":"Part A-SAD: Cohort 3: Tofersen 40 mg","type":"EXPERIMENTAL"},{"label":"Part A-SAD: Cohort 4: Tofersen 60 mg","type":"EXPERIMENTAL"},{"label":"Part B-MAD: Combined Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B-MAD: Cohort 5: Tofersen 20 mg","type":"EXPERIMENTAL"},{"label":"Part B-MAD: Cohort 6: Tofersen 40 mg","type":"EXPERIMENTAL"},{"label":"Part B-MAD: Cohort 7: Tofersen 60 mg","type":"EXPERIMENTAL"},{"label":"Part B-MAD: Cohort 8: Tofersen 100 mg","type":"EXPERIMENTAL"},{"label":"Part C-Pivotal: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part C-Pivotal: Tofersen 100 mg","type":"EXPERIMENTAL"}],"summary":"The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation.\n\nThe secondary objective of Parts A and B of this study is to evaluate the effects of tofersen on levels of total SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part C are to evaluate the safety, tolerability, pharmacodynamic (PD), and biomarker effects of tofersen.","primaryOutcome":{"measure":"Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Part A: First dose up to Day 63; Part B: First dose up to Day 289","effectByArm":[{"arm":"Part A-SAD: Combined Placebo","deltaMin":2,"sd":null},{"arm":"Part A-SAD: Cohort 1: BIIB067 10 mg","deltaMin":2,"sd":null},{"arm":"Part A-SAD: Cohort 2: BIIB067 20 mg","deltaMin":3,"sd":null},{"arm":"Part A-SAD: Cohort 3: BIIB067 40 mg","deltaMin":3,"sd":null},{"arm":"Part A-SAD: Cohort 4: BIIB067 60 mg","deltaMin":6,"sd":null},{"arm":"Part B-MAD: Combined Placebo","deltaMin":12,"sd":null},{"arm":"Part B-MAD: Cohort 5: BIIB067 20 mg","deltaMin":10,"sd":null},{"arm":"Part B-MAD: Cohort 6: BIIB067 40 mg","deltaMin":9,"sd":null},{"arm":"Part B-MAD: Cohort 7: BIIB067 60 mg","deltaMin":9,"sd":null},{"arm":"Part B-MAD: Cohort 8: BIIB067 100 mg","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":11},"locations":{"siteCount":40,"countries":["United States","Australia","Belgium","Canada","Denmark","France","Germany","Italy","Japan","Poland","South Korea","United Kingdom"]},"refs":{"pmids":["36129998","32640130"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":5},"commonTop":["Procedural pain","Headache","Fall","Post lumbar puncture syndrome","Pain in extremity"]}}